UNSPSC 51386602: Aloe/hydrocortisone

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE200. This VA Drug Class (DE200) classifies this compound as belonging to the group ANTI-INFLAMMATORY, TOPICAL.

UNSPSC 51386602 Aloe/hydrocortisone is a Commodity code that in practice captures state and local procurement of pharmaceutical products, though the recent opportunities show minimal activity directly aligned with the code's nominal scope. The three recent solicitations tagged under this code involve naloxone and drug deactivation systems, a market-intelligence RFI on direct-to-manufacturer pharmacy programs, and a multistate cooperative purchasing agreement for generic pharmaceuticals and over-the-counter products—none of which center on aloe or hydrocortisone formulations. State and local issuers across this code include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). The mix reflects both single-jurisdiction and multistate procurement vehicles for pharmaceutical supply.

Geographic activity is concentrated in Florida, Texas, and Minnesota based on recent postings. Seminole County posted an IFB for naloxone and drug deactivation systems on June 30, 2026, with a response deadline of July 26, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries; the contract includes a two-year initial term with an optional one-year renewal and was potentially FEMA-funded. Texas HHS Commission issued a Request for Information on April 3, 2026, to gather vendor capabilities on direct-to-manufacturer prescription programs without a formal competitive timeline, designed to inform future procurement strategy rather than commit to immediate contracting. The Minnesota Department of Administration's MMCAP issued an RFP posted January 20, 2026, with a March 26, 2026, response deadline for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson), with contract effectiveness July 1, 2026. The code shows little relevant recent activity directly tied to aloe or hydrocortisone procurement; the tagging appears to reflect broader pharmaceutical categorization rather than targeted demand for this specific commodity.